NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CellSight Technologies

CellSight Technologies

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://cellsighttech.com/

Last Round

SBIR Phase

II

Sep 16, 2022

Total Funding Raised

$2.19M

Company Overview

CellSight Technologies is a biotechnology company that develops PET imaging tracers for diagnostic imaging in the immunotherapy field.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Imaging, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

molecular imagingimmuno-oncologyPET imagingT-cell activationPET tracerradiotracerimmunotherapy monitoringimmune response monitoringoncology imagingprecision medicineclinical trial imagingnon-invasive diagnosticsbiotech imagingdrug development toolstheranostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellSight Technologies Comparables

Compare CellSight Technologies with similar companies based on industry and business-model similarity.

CellSight Technologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CytoSite Bio
88%
imuveo
83%
Telix Pharmaceuticals
81%

CellSight Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SBIR Phase IISep 16, 2022
Corporate FundingNov 8, 2017

Key People

Founding team and executive leadership

Sam Quezada

Co-founder & COO

Founding Team

CellSight Technologies Investors

Notable investors and investment history

CellSight Technologies investors
InvestorRounds
National Cancer InstituteSBIR Phase II, SBIR Phase I
Boehringer IngelheimCorporate Funding
NIH RADxGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 23, 2025

    Monthly visitors increased 45% MoM, reaching 1.1K.

  • Sep 16, 2022

    Raised $2M with the National Cancer Institute as lead investor.

CellSight Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CellSight Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CellSight Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range4
Year Founded2009
Last FundingSep 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.